On Dec. 10, Bristol-Myers Squibb made what it called its final offer to buy Celgene. But it turns out that wasn’t the case. Just days before a Jan. 2 deadline, with Celgene's shares reeling, Bristol-Myers pulled its $57-per-share bid—and won a lower price instead.
